PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Genes Immun. Author manuscript; available in PMC 2012 July 2.
Published in final edited form as:
PMCID: PMC3387803
NIHMSID: NIHMS382642

The rs4774 CIITA missense variant is associated with risk of systemic lupus erythematosus

Paola G. Bronson, Ph.D., M.P.H.,1 Benjamin A. Goldstein, Ph.D.,1,2 Patricia P. Ramsay, M.P.H.,1 Kenneth B. Beckman, Ph.D.,3 Janelle A. Noble, Ph.D.,4 Julie A. Lane,4 Michael F. Seldin, M.D., Ph.D.,5 Jennifer A. Kelly, M.P.H.,6 John B. Harley, M.D., Ph.D.,7,8 Kathy L. Moser, Ph.D.,6 Patrick M. Gaffney, Ph.D.,6 Timothy W. Behrens, M.D.,9 Lindsey A. Criswell, M.D. M.P.H.,10 and Lisa F. Barcellos, Ph.D.1

Abstract

The major histocompatibility complex (MHC) class II transactivator gene (CIITA) encodes an important transcription factor required for HLA class II MHC-restricted antigen presentation. MHC genes, including the HLA class II DRB1*03:01 allele, are strongly associated with systemic lupus erythematosus (SLE). Recently the rs4774 CIITA missense variant (+1632G/C) was reported to be associated with susceptibility to multiple sclerosis. In the current study, we investigated CIITA, DRB1*03:01 and risk of SLE using a multi-stage analysis. In stage 1, 9 CIITA variants were tested in 658 cases and 1,363 controls (N = 2,021). In stage 2, rs4774 was tested in 684 cases and 2,938 controls (N = 3,622). We also performed a meta-analysis of the pooled 1,342 cases and 4,301 controls (N = 5,643). In stage 1, rs4774*C was associated with SLE (odds ratio [OR] = 1.24, 95% confidence interval [95% CI] = 1.07–1.44, P = 4.2 × 10−3). Similar results were observed in stage 2 (OR = 1.16, 95% CI = 1.02–1.33, P = 8.5×10−3) and the meta-analysis of the combined dataset (OR = 1.20, 95% CI = 1.09–1.33, Pmeta = 2.5×10−4). In all three analyses, the strongest evidence for association between rs4774*C and SLE was present in individuals who carried at least one copy of DRB1*03:01 (Pmeta= 1.9×10−3). Results support a role for CIITA in SLE, which appears to be stronger in the presence of DRB1*03:01.

Keywords: systemic lupus erythematosus, autoimmunity, major histocompatibility complex, HLA, CIITA, MHC2TA

Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease and is characterized by autoantibody production and altered immune complex formation and clearance. SLE has a strong genetic component, as demonstrated by twin and other family studies. Major histocompatibility complex (MHC) genes on chromosome 6p21, particularly the class II HLA-DRB1*03:01 allele, are strongly associated with increased risk of developing SLE. However, MHC genes only account for a portion of the genetic risk. Several non-MHC genes have recently been associated with risk of SLE, including PTPN22, STAT4 and TNFAIP3, and 6 genomewide association (GWA) studies have collectively established more than 20 risk loci.

The MHC class II transactivator gene (CIITA, also called MHC2TA) encodes the CIITA protein, a transcription factor essential for the expression of HLA class II molecules and involved in the expression of HLA class I molecules.1,2 CIITA spans 47.8 kb on chromosome 16p13, with four alternate first exons in a 12kb promoter region (I–IV).3 Mutations in CIITA cause a rare and severe immunodeficiency characterized by HLA class II deficiency (bare lymphocyte syndrome).2 Thus, CIITA is an attractive candidate for genetic studies of autoimmune diseases for which HLA associations have been well established. Recently, the CIITA +1632G/C missense mutation (rs4774, alias +1614G/C) showed strong evidence for association with multiple sclerosis (MS) in the presence of DRB1*15:01, a well-established MS risk allele.4

The purpose of this study was to investigate association between the CIITA rs4774 variant and neighboring SNPs in the region and risk of developing SLE, and to identify interactions between CIITA variants and the established SLE HLA-DRB1*03:01 risk allele. A total of 1,463 patients from a multi-center, well-characterized dataset (University of California, San Francisco; Oklahoma Medical Research Foundation; University of Minnesota) were included in this analysis (Table 1).5 All individuals were of European ancestry, as determined by ancestry informative genetic markers.

Table 1
SLE study cohorts used for CIITA analyses

In stage 1, we conducted allelic tests of association for 9 CIITA SNPs in 658 cases and 1,363 controls (N = 2,021) and stratified on the presence and absence of DRB1*03:01. DRB1 data was not available for the controls, so instead SNP r2187668 was used as a proxy to tag the DRB1*0301 allele as previously described.6 In stage 2, rs4774, the only associated SNP, was tested in 684 cases and 2,938 controls (N = 3,622). We performed a meta-analysis as well as interaction tests in the pooled dataset comprised of 1,342 cases and 4,301 controls (N = 5,643).

As previously reported, DRB1*03:01 was strongly associated with SLE in both stages 1 and 2 (odds ratio [OR] = 1.96, 95% confidence interval [95% CI] = 1.64 to 2.34, P = 1×10−4, and OR = 1.61, 95% CI = 1.38 to 1.88, P = 1×10−6, respectively).5 After correcting for multiple testing in the overall sample, association was observed between rs4774 and SLE (OR = 1.24, 95% CI = 1.07–1.44, P = 4.2 × 10−3; DRB1*03:01+: OR = 1.27, 95% CI = 1.06–1.53, P = 9×10−3) (Table 2). In stage 2, rs4774*C was associated with SLE (OR = 1.16, 95% CI = 1.02–1.33, P = 8.5×10−3; DRB1*03:01+: OR = 1.23, 95% CI = 0.98–1.54, P = 3.5×10−2) (Table 3). In the meta-analysis, rs4774*C was associated with SLE (OR = 1.20, 95% CI = 1.09–1.33, P=2.5×10−4; DRB1*03:01+: OR = 1.25, 95% CI = 1.09–1.45, Pmeta = 1.9×10−3) (Table 3). Evidence for interaction between DRB1*03:01 and rs4774*C was not observed in either case-control or case-only analyses (data not shown) (Supplementary Table 1).

Table 2
Location, minor allele frequencies (MAF), odds ratios (OR), 95% confidence intervals (95% CI), and P-values from allelic tests in stage 1.
Table 3
Results from allelic tests of the rs4774 missense mutation in stages 1 and 2 and the combined sample, stratified by the presence of DRB1*03:011.

The CLEC16A gene is adjacent to CIITA on chromosome 16, and CLEC16A has been previously established as a risk locus for several autoimmune diseases, including SLE (rs12708716*A, OR = 1.16, P = 1.6×10−4).7 Evidence for association between the CLEC16A rs12599402*A allele and SLE was also reported in a Chinese population (GWA study: OR = 1.27, 95% CI = 1.10–1.47, P = 1.4×10−3; replication study: OR = 1.23, 95% CI = 1.14–1.33, P = 2.5×10−6; combined: OR = 1.23, 95% CI = 1.15–1.33, P = 1.3×10−8).8 To confirm that association observed between rs4774 and SLE in the current study was not due to linkage disequilibrium (LD) with CLEC16A, we performed an allelic test of the rs12708716*A risk allele in stages 1 and 2. We also conducted a meta-analysis of the combined sample. Results from our analyses did not provide evidence for association between CLEC16A and SLE (stage 1: OR = 1.06, 95% CI = 0.93–1.22, P = 0.39; stage 2: OR = 1.10, 95% CI = 0.97–1.25, P = 0.13; pooled OR = 1.08, 95% CI = 0.98–1.19, Pmeta = 0.09). However, our study had limited power to observe extremely modest effects for the CLEC16A variant in SLE. We examined LD patterns between 14 CLEC16A SNPs and 24 CIITA SNPs in the controls from stage 1, 43 CLEC16A SNPs and 19 CIITA SNPs in the controls from stage 2, and 274 CLEC16A SNPs and 40 CIITA SNPs in HapMap samples of northern and western European origin (CEU, release 24) (data not shown). There was no evidence of LD between CIITA and CLEC16A in the controls (r2 ≤ 0.10). The patterns of LD derived from three independent samples support a primary role for CIITA variation that is independent of CLEC16A in SLE.

The rs4774*C variant, located in exon 11, causes an amino acid substitution from glycine to alanine at amino acid position 500. The rs4774*C minor allele is ancestral, based on chimpanzee DNA.9,10 Based on sequence homology and physical properties of amino acids, this amino acid substitution is predicted to have a tolerable effect on protein function.11 However, the exact functional consequences that result are not known. Steimle et al. previously tested the functionality of this amino acid substitution and did not observe any difference between CIITA G500 and A500.2 However, their experiment evaluated G500A jointly with a three nucleotide insertion that causes an amino acid substitution from lysine to isoleucine-glutamic acid at amino acid position 120.2 It would be worthwhile to reassess the functional effect of G500A individually, and also to utilize a more sensitive method that can detect minor differences in the efficiency of CIITA.12 Interestingly, exon 11 contains an exonic splice enhancer (ESE) density (0.27) that is more similar to exons containing splice-affecting variants (SAVs) than randomly sampled exons with a similar size distribution (0.38).13 The lower ESE density, closer to ESE densities in introns, suggests a weakened exon definition that may be more vulnerable to variants that further modulate ESE density and could potentially lead to exon skipping.13 Animal models provide some evidence supporting a role for CIITA in autoimmune disease pathogenesis. CIITA transgenic mice with over-expression of CIITA in helper T cells demonstrated aggravated oxazolone-induced colitis compared to wild type mice, due to elevated IL-4 production and Th2 inflammation.14

Other studies have examined CIITA variation in SLE with conflicting findings. A previous study examining SLE risk and the rs4774 variant did not observe evidence for association (OR = 0.97, 95% CI = 0.77–1.20, P = 0.7).15 However, power was limited due to relatively small sample size (394 cases and 514 controls). In addition, investigators did not stratify by DRB1*03:01 or restrict samples by genetic ancestry information to reduce the possibility of bias from potential population structure. Association between the CIITA –168A/G promoter polymorphism (rs3087456) and SLE risk has been previously reported in a Japanese population.16 In contrast, studies in Swedish and Spanish populations do not support these findings.15,17 Our results, based on association testing for rs12928665 as a tagging SNP in stage 1, do not support a role for rs3087456 in SLE.4

It is important to note that results from recent GWA studies in SLE have not provided evidence for association with CIITA.1825 However, the rs4774 variant identified in this study (or any SNPs that are known to tag it) have not been included in previous investigations.26 Further, HLA DRB1*03:01 status was not available for study subjects. There are currently two SNPs (rs4780334, rs7196089) known to be in strong LD with rs4774 (r2 = 0.96); they are both intronic, and therefore, do not yet explain the functional relevance of the rs4774 finding.26 Our current CIITA results would not meet stringent genomewide significance. Nevertheless it is possible that a vast number of modest effects failing the stringent GWA significance tests are responsible for some of the unexplained heritability in SLE.27 A recent study on the missing heritability of height provided evidence that 45% of the variance of height can be explained by considering at least 300,000 SNPs simultaneously, and that the remaining heritability could be due to incomplete LD between casual variants and the genotyped SNPs.27 This indicates that candidate gene and pathway-based approaches are a useful complementary strategy to GWA studies.

Interestingly, it appears that genetic variation in CIITA may be important for some autoimmune diseases but not others. Despite initial reports indicating otherwise, a meta-analysis of over 16,000 RA cases and controls revealed no evidence for association with the -168A/G polymorphism.28,29 Furthermore, common variation in CIITA does not appear to play a role in RA.30 In contrast, the CIITA gene region has reached genomewide significance in recent studies of both ulcerative colitis (UC) and celiac disease.31,32 McGovern et al. report evidence for association between the intronic CIITA rs4781011*T variant and risk of UC (P = 3.2×10−6, combined weighted analysis of three GWA screens [GWAS1: OR = 1.15; GWAS2 OR = 1.28; GWAS3 OR = 1.16] and two replication studies [OR = 1.06, OR = 1.18]) (N = 13,073 individuals of European descent). Through tagging based on strong LD, rs4781011 was also captured in the current study; however, a role for this variant in SLE was not supported. Dubois et al. cite evidence for association between the CIITA-CLEC16A-SOCS1 gene region and increased risk of celiac disease.32 The C16orf75 rs12928822*C allele demonstrated the strongest effect (OR = 1.16, 95% CI = 1.10 to 1.22, P = 3.1×10−8, combined weighted analysis of GWA screen and replication study) (N = 25,885 individuals of European descent).32 Within the CIITA region, the strongest effect was for the rs6498114*T promoter allele (OR = 1.11, 95% CI = 1.06 to 1.16, P = 1×10−5).32 Results from our analysis of rs6498114 did not support a role for this variant in SLE. Functional relevance for either associated SNP is not known at this time.

In conclusion, this is the largest study of CIITA and SLE to date, and the first study of CIITA in SLE to examine potential interactions between CIITA variants and the established SLE HLA-DRB1*03:01 risk allele. We are the first to report association between the rs4774 missense mutation and SLE, which appears to be stronger in the presence of DRB1*03:01. Future studies are warranted to examine the potential functional significance of the rs4774 variant, and consider the contribution of rare CIITA variants to SLE risk.

Supplementary Material

Suppl Table 1

Acknowledgments

We would like to thank the International MS Genetics Consortium for contributing genetic data to this study. We also thank Suzanne May, Farren Briggs, Alan Hubbard and Gary Artim. This work was supported by an REF/Abbott Graduate Student Achievement Award from the American College of Rheumatology (PB), a Kirkland Scholar Award from the Mary Kirkland Center for Lupus Research (LAC), the Alliance for Lupus Research (JBH, KLM, LAC), the U.S. Department of Veterans Affairs (JBH), Lupus Foundation Minnesota (KLM) and NIH grants F31-AI075609 (PGB), R01-AR44804 (LAC), R01-AR052300 (LAC), K24-AR02175 (LAC), P60 AR053308 (LAC), P01 AR049084 (JBH), R01 AR42460 (JBH), R01 AR043274–14 (KLM) and N01 AR62277 (JBH) from NIAMS, R37 AI24717 (JBH), P01 AI083194 (JBH), 5R01 A1063274–06 (PMG) from NIAID, and P20-RR020143 (JBH) from NCRR. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NIAID or NCRR. This study was performed in part in the General Clinical Research Center, Moffitt Hospital, UCSF, with funds provided by the National Center for Research Resources, 5-M01-RR-00079, U.S. Public Health Service. This study makes use of data generated by the WTCCC; a full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk, and funding for the project was provided by the Wellcome Trust under award 076113.

Footnotes

Supplementary information is available at Gene & Immunity’s website.

References

1. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med. 1995;181(2):765–767. [PMC free article] [PubMed]
2. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome) Cell. 1993;75(1):135–146. [PubMed]
3. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997;16(10):2851–2860. [PubMed]
4. Bronson PG, Caillier S, Ramsay PP, McCauley JL, Zuvich RL, De Jager PL, et al. CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. Hum Mol Genet. 19(11):2331–2340. [PMC free article] [PubMed]
5. Barcellos LF, May SL, Ramsay PP, Quach HL, Lane JA, Nititham J, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 2009;5(10):e1000696. [PMC free article] [PubMed]
6. de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38(10):1166–1172. [PMC free article] [PubMed]
7. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1228–1233. [PMC free article] [PubMed]
8. Zhang Z, Cheng Y, Zhou X, Li Y, Gao J, Han J, et al. Polymorphisms at 16p13 are associated with systemic lupus erythematosus in the Chinese population. J Med Genet. 48(1):69–72. [PubMed]
9. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic acids research. 2001;29(1):308. [PMC free article] [PubMed]
10. Spencer CCA, Deloukas P, Hunt S, Mullikin J, Myers S, Silverman B, et al. The Influence of Recombination on Human Genetic Diversity. PLoS Genet. 2006;2(9):e148. [PubMed]
11. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863–874. [PubMed]
12. Steimle V. 2010
13. Woolfe A, Mullikin JC, Elnitski L. Genomic features defining exonic variants that modulate splicing. Genome Biol. 11(2):R20. [PMC free article] [PubMed]
14. Kim TW, Park HJ, Choi EY, Jung KC. Overexpression of CIITA in T cells aggravates Th2-mediated colitis in mice. J Korean Med Sci. 2006;21(5):877–882. [PMC free article] [PubMed]
15. Sanchez E, Sabio JM, Jimenez-Alonso J, Callejas JL, Camps M, de Ramon E, et al. Study of two polymorphisms of the MHC2TA gene with systemic lupus erythematosus. Rheumatology. 2008;47(1):102–103. [PubMed]
16. Okamoto H, Kaneko H, Terai C, Kamatani N. Protective effect of A at position-168 in the type III promoter of the MHCIITA gene in systemic lupus erythematosus. Ann Rheum Dis. 2007;66(9):1263–1264. [PMC free article] [PubMed]
17. Linga-Reddy MVP, Gunnarsson I, Svenungsson E, Sturfelt G, Jonsen A, Truedsson L, et al. A polymorphic variant in the MHC2TA gene is not associated with systemic lupus erythematosus. Tissue Antigens. 2007;70(5):412–414. [PubMed]
18. Hindorff LA, Junkins HA, Hall PN, Mehta JPTA. [Accessed 6/7/2010];M A Catalog of Published Genome-Wide Association Studies. Available at www.genome.gov/gwastudies.
19. Kozyrev SV, Abelson A-K, Wojcik J, Zaghlool A, Linga Reddy MVP, Sanchez E, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008;40(2):211–216. [PubMed]
20. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008;358(9):900–909. [PubMed]
21. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40(2):204–210. [PubMed]
22. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1059–1061. [PMC free article] [PubMed]
23. Yang J, Yang W, Hirankarn N, Ye DQ, Zhang Y, Pan HF, et al. ELF1 is associated with systemic lupus erythematosus in Asian populations. Hum Mol Genet. 20(3):601. [PubMed]
24. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009 [PubMed]
25. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 6(2) [PMC free article] [PubMed]
26. Lawrence R, Day-Williams AG, Mott R, Broxholme J, Cardon LR, Zeggini E. GLIDERS--a web-based search engine for genome-wide linkage disequilibrium between HapMap SNPs. BMC bioinformatics. 2009;10:367. [PMC free article] [PubMed]
27. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 42(7):565–569. [PMC free article] [PubMed]
28. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet. 2005;37(5):486–494. [PubMed]
29. Bronson PG, Criswell LA, Barcellos LF. The MHC2TA-168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association. Ann Rheum Dis. 2008;67(7):933–936. [PMC free article] [PubMed]
30. Bronson PG, Ramsay PP, Seldin MF, Gregersen PK, Criswell LA, Barcellos LF. CIITA is not associated with risk of developing rheumatoid arthritis. Genes Immun [PMC free article] [PubMed]
31. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 42(4):332–337. [PMC free article] [PubMed]
32. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet. 42(4):295–302. [PMC free article] [PubMed]
33. Tian C, Plenge RM, Ransom M, Lee A, Villoslada P, Selmi C, et al. Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genet. 2008;4(1):29–39. [PubMed]
34. Kosoy R, Nassir R, Tian C, White PA, Butler LM, Silva G, et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat. 2009;30(1):69–78. [PMC free article] [PubMed]
35. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies. Genetics. 2003;164(4):1567–1587. [PubMed]
36. Genome-wide association study of 14,000 cases of seven common diseases and 3, 000 shared controls. Nature. 2007;447(7145):661–678. [PMC free article] [PubMed]
37. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–265. [PubMed]
38. International_HapMap_Consortium. A haplotype map of the human genome. Nature. 2005;437(7063):1299–1320. [PMC free article] [PubMed]
39. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–575. [PubMed]
40. Clarke GM, Pettersson FH, Morris AP. A comparison of case-only designs for detecting gene x gene interaction in rheumatoid arthritis using genome-wide case-control data in Genetic Analysis Workshop 16. BMC Proc. 2009;3 (Suppl 7):S73. [PMC free article] [PubMed]
41. Yang Q, Khoury MJ, Sun F, Flanders WD. Case-Only Design to Measure Gene-Gene Interaction. Epidemiology. 1999;10(2):167–170. [PubMed]